WASHINGTON, Nov. 16, 2011 /PRNewswire-USNewswire/ -- The Personalized Medicine Coalition (PMC) released today the 3rd edition of its landmark report, The Case for Personalized Medicine. The report documents the growth of commercially available personalized medicine products from 13 in 2006 to 72 today, and examines opportunities for the continued development and adoption of personalized medicine as the cost of genetic sequencing declines, the pharmaceutical industry increases its commitment to personalized approaches to drug development and the public policy landscape evolves.
"The Case for Personalized Medicine documents personalized medicine's remarkable progress, evidenced by improved patient outcomes, shifting research models and increased industry investment. Yet it underscores the necessary steps required to align regulatory and reimbursement systems, thereby removing barriers that will increase personalized medicine innovation and speed its adoption," said Edward Abrahams, Ph.D., President of the Personalized Medicine Coalition.
Highlights from the report include:
- A compendium listing the 72 commercially available prominent personalized medicine products, grouped by indication, highlights the increasing diversity of personalized medicine drugs and diagnostic tests for conditions including arthritis, cancer, cardiovascular disease, infectious diseases, organ transplants and psychiatric disorders;
- Real-world examples that demonstrate how personalized medicine is shifting the focus in health care from reaction to prevention, reducing trial-and-error prescribing, making drugs safer, improving health outcomes, and reducing costs to the health care system;
- A discussion of the numerous policies which impact personalized medicine, highlighting the U.S. Food and Drug Administration's increasing commitment to personalized medicine;
- An examination of the technologies